Relypsa Inc Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 49 rows in 2015. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2015-12-31: Reporting owner Stahl Wilhelm; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2015-12-31: Reporting owner Stahl Wilhelm; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2015-12-09: Reporting owner Berman Lance; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2015-12-07: Reporting owner Orwin John A; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | Stahl Wilhelm Officer (SVP, Chief Technology Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,291 27,759 owned after | $3.96 exercise price | 2016-01-04 | |
| 2015-12-31 | Stahl Wilhelm Officer (SVP, Chief Technology Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,709 46,597 owned after | $3.96 exercise price | 2016-01-04 | |
| 2015-12-09 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −750 25,414 owned after | $7.40 exercise price | 2015-12-09 | |
| 2015-12-07 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 727,877 owned after | $7.40 exercise price | 2015-12-09 | |
| 2015-12-07 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,896 10,668 owned after | $3.96 exercise price | 2015-12-09 | |
| 2015-12-07 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,349 21,765 owned after | $3.96 exercise price | 2015-12-09 | |
| 2015-12-07 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,755 26,164 owned after | $7.40 exercise price | 2015-12-09 | |
| 2015-12-04 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 737,877 owned after | $7.40 exercise price | 2015-12-04 | |
| 2015-12-02 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 757,877 owned after | $7.40 exercise price | 2015-12-04 | |
| 2015-08-10 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,000 105,000 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Harrison Stephen D Officer (SVP & Chief Scientific Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Garland J. Scott Officer (SVP & Chief Commercial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Corbett Mary Officer (SVP, Human Resources) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | BALL KRISTINE M Officer (Chief Financial Officer & SVP) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-08-10 | Stahl Wilhelm Officer (SVP, Chief Technology Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $28.38 exercise price | 2015-08-12 | |
| 2015-07-31 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 777,877 owned after | $7.40 exercise price | 2015-08-03 | |
| 2015-07-30 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 782,877 owned after | $7.40 exercise price | 2015-08-03 | |
| 2015-06-04 | MCGIRR DAVID W J Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-09 | |
| 2015-06-04 | SPIEGELMAN DANIEL K Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-04 | Hillan Kenneth J. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-04 | HASTINGS PAUL J Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-04 | Butler John P. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-04 | Schuetz Thomas J. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-04 | Torley Helen Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,500 4,500 owned after | $35.79 exercise price | 2015-06-08 | |
| 2015-06-01 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,555 802,877 owned after | $7.40 exercise price | 2015-06-02 | |
| 2015-05-29 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 811,432 owned after | $7.40 exercise price | 2015-06-02 | |
| 2015-05-11 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,834 69,543 owned after | $3.96 exercise price | 2015-05-13 | |
| 2015-04-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,832 75,377 owned after | $3.96 exercise price | 2015-04-13 | |
| 2015-03-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,331 12,795 owned after | $4.65 exercise price | 2015-03-12 | |
| 2015-03-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,503 81,209 owned after | $3.96 exercise price | 2015-03-12 | |
| 2015-03-05 | BALL KRISTINE M Officer (Chief Financial Officer & SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 122,872 owned after | $3.96 exercise price | 2015-03-05 | |
| 2015-03-04 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,052 215 owned after | $4.65 exercise price | 2015-03-06 | |
| 2015-03-04 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −948 25,214 owned after | $3.79 exercise price | 2015-03-06 | |
| 2015-02-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,580 24,564 owned after | $3.96 exercise price | 2015-02-25 | |
| 2015-02-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,580 33,114 owned after | $3.96 exercise price | 2015-02-25 | |
| 2015-02-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,840 30,919 owned after | $7.40 exercise price | 2015-02-25 | |
| 2015-02-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,834 16,126 owned after | $4.65 exercise price | 2015-02-10 | |
| 2015-01-22 | Torley Helen Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $36.83 exercise price | 2015-01-26 | |
| 2015-01-21 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,081 0 owned after | $2.76 exercise price | 2015-01-23 | |
| 2015-01-21 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −33,368 8,783 owned after | $3.96 exercise price | 2015-01-23 | |
| 2015-01-21 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,551 37,611 owned after | $3.96 exercise price | 2015-01-23 | |
| 2015-01-21 | BALL KRISTINE M Officer (Chief Financial Officer & SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 125,872 owned after | $3.96 exercise price | 2015-01-23 | |
| 2015-01-21 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 9,267 owned after | $4.65 exercise price | 2015-01-23 | |
| 2015-01-14 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 8,081 owned after | $2.76 exercise price | 2015-01-16 | |
| 2015-01-12 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,834 21,960 owned after | $4.65 exercise price | 2015-01-14 | |
| 2015-01-02 | Harrison Stephen D Officer (SVP & Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $30.80 exercise price | 2015-01-06 |